People with an active infection, cancer that has not been reviewed by their oncologist, unstable serious illness, or an unresolved collection, allergy or anesthesia risk should postpone elective stem cell procedures pending medical assessment. If you are pregnant or breastfeeding, do not assume an elective procedure is safe; ask for a product-specific review before proceeding. Avoid offers that promise a cure, replace necessary treatment, or lack credible evidence and appropriate regulatory oversight.
A temporary medical delay is different from an unsuitable treatment. A specialist may reassess you after an infection clears, but medical clearance alone cannot establish that a cell product works. The FDA has received reports of infections, tumor formation and other serious harms from unapproved regenerative products Important patient and consumer information about regenerative medicine therapies.

This is general information, not personal medical advice. These precautions concern elective clinic procedures, not a recommendation to refuse a medically indicated blood-forming stem cell transplant. Transplant eligibility depends on the disease, treatment plan and individual risks Stem cell transplant.
If you have an active infection
If you have a fever, spreading redness, urinary symptoms, a dental infection or another suspected infection, contact your treating doctor before an elective collection or injection. Report recent antibiotics, hepatitis, HIV and tuberculosis exposure so the team can decide which tests and precautions apply. A history of infection is not, by itself, a universal lifetime exclusion.
Patient infection and product contamination are separate risks. Chemotherapy used before some blood-forming transplants increases infection risk; that does not mean every clinic infusion involves chemotherapy Stem cell transplant. Unapproved cell products can also introduce infection through contamination during processing Important patient and consumer information about regenerative medicine therapies.
In a 2018 U.S. investigation, 12 patients in 3 states developed infections after receiving contaminated, unapproved umbilical cord blood-derived products for uses other than blood or immune reconstitution. All 12 were hospitalized. Infections included bloodstream infections, joint infections and epidural abscesses; bacteria were found in unopened vials. The product was recalled on 28 September 2018 Mm6750a5.htm.
That outbreak does not give a general infection rate for all cell treatments.
Bring infection dates, test results and antibiotic details. Ask what must improve before reassessment and which screening tests are required for the proposed procedure. Include this review in your medical travel planning for Japan, before committing to treatment dates.
If you have cancer or an unexplained finding
Postpone an unrelated elective cell injection while a new lump, unexplained bleeding, weight loss or an abnormal scan is being investigated. If you have cancer, ask your oncologist to review the proposed product and timing. Blood-forming stem cell transplantation is established care for selected cancers and blood disorders, including some leukemias, lymphomas and multiple myeloma; cancer is therefore not a blanket reason to avoid every stem cell treatment Stem cell transplant.
The FDA lists tumor formation among reported harms of unapproved regenerative products; this is not proof that every cell product causes cancer Important patient and consumer information about regenerative medicine therapies. Bring your pathology, stage, treatment history and oncology advice. Ask whether the proposal could interfere with your cancer treatment or follow-up.
If you are pregnant or breastfeeding
Tell the reviewing doctor if you are pregnant, might be pregnant, are breastfeeding or plan a pregnancy soon. Safety must be assessed for the exact product and each accompanying procedure or medicine, not for the label “stem cell therapy” as a whole. For an elective, unproven intervention, ask whether postponement is the safer option and what pregnancy or breastfeeding data are available. This is a precaution, not a claim that all cell therapies have the same reproductive risks.
If you have heart, lung, liver or kidney disease
A chronic diagnosis does not automatically rule you out. What matters is how stable your condition is and whether you can tolerate the exact treatment. NCI includes other serious health problems and the ability to tolerate high-dose chemotherapy among blood-forming transplant eligibility considerations Stem cell transplant. For an elective clinic procedure, ask your specialist to review recent deterioration, oxygen needs, dialysis, bleeding problems or poorly controlled diabetes before collection, sedation or infusion.
Diabetes and high blood pressure are common causes of chronic kidney disease in adults. Kidney failure may require dialysis or a kidney transplant; an elective cell injection should not replace established care Chronic kidney disease ckd. NIDDK explains that a GFR below 60 may indicate kidney disease, while a GFR of 15 or less indicates kidney failure. A urine albumin-to-creatinine ratio above 30 mg/g may indicate kidney disease and may need repeat testing Tests diagnosis. These are kidney assessment thresholds, not universal cutoffs for stem cell eligibility.
Bring recent organ-function results and specialist advice. Ask how fluids, medicines and follow-up would be managed. Keep the liver and kidney dysfunction information separate from evidence that a particular product benefits your condition. Questions about the proposed procedure belong in your discussion of stem cell treatment safety in Japan.
If you take daily medicines or worry about anesthesia
Taking daily medicine is not, by itself, a reason to avoid all cell therapy. Give the team a complete list, including blood thinners, antiplatelet drugs, steroids, immunosuppressants, cancer treatment and diabetes medicines. Do not stop or change a prescription to qualify; have the reviewing team coordinate with your prescriber.
If cells would be collected by liposuction, remember that this is surgery. MedlinePlus lists infection, bleeding, blood clots, fat embolism and medicine reactions among its risks, and advises assessment of conditions such as heart disease, diabetes and lung problems before surgery 002985.htm. These collection risks do not apply identically to products that do not require liposuction.
Report previous anaphylaxis, medicine allergies and anesthesia complications. Ask for the product’s ingredients and whether it contains a preservative or freezing agent relevant to your allergy history. For children or frail adults, ask how consent, procedure fitness and aftercare will be assessed.
Your own cells do not require donor HLA matching, but “autologous” does not mean risk-free. In donor blood-forming transplantation, HLA matching and graft-versus-host disease are important considerations Stem cell transplant. The distinction between autologous and allogeneic stem cells is not a substitute for assessing the exact product and route.
If your diagnosis has no proven cell benefit
If a clinic cannot identify the product, explain its legal status or provide relevant human evidence, do not treat a sales claim as proof of benefit. Ask whether the evidence matches your diagnosis, disease stage, cell source, processing and administration route. The indications and contraindications guide can help organize questions, but is not independent evidence of efficacy.
Japan’s regenerative medicine provision-plan framework is separate from product marketing approval. A submitted plan is not proof that a treatment works Index. Conditional, time-limited product approvals also have a defined scope and require further data collection; they are not blanket approval of all cell treatments 0003.
Approvals are product- and indication-specific. For example, on 18 December 2024 the FDA approved Ryoncil, a donor bone marrow-derived mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. That approval does not establish benefit for unrelated clinic treatments Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.
An appropriately regulated clinical trial may study an intervention whose benefit is still uncertain. Ask about oversight, eligibility, alternatives, known risks and follow-up; trial registration alone does not establish efficacy. FDA warns that registration or a ClinicalTrials.gov listing does not mean an unapproved product is legally marketed Important patient and consumer information about regenerative medicine therapies. Use those distinctions when assessing a stem cell hospital in Japan, and reject promises of a guaranteed cure.
What to ask first
Suppose you take a blood thinner and are offered fat collection followed by an infusion. Ask who will coordinate the medicine plan, whether you can safely undergo collection, and what evidence supports the infusion. Clearance for surgery addresses collection risk; it does not prove the infusion will help. Do not change your medicine while waiting for that discussion.
| Your situation | What the doctor needs to see | Useful question |
|---|---|---|
| New fever, infection or abnormal labs | Dates, cultures, imaging, antibiotics, treating doctor | Postpone collection, injection, or both, and when to recheck? |
| Cancer history or new finding | Pathology, stage, treatment history, oncology letter | Does this interfere with cancer care or surveillance? |
| Pregnancy or breastfeeding | Pregnancy status, medicines, anesthesia plan | Which step needs deferral, and who clears a future date? |
| Heart, lung, liver or kidney disease | Specialist notes, ECG or echo if done, liver and kidney labs, pressure and glucose logs | Can I tolerate collection, sedation and follow-up? |
| Blood thinners or immunosuppressants | Full drug list with doses, prescriber contacts | What medicine plan does my prescriber recommend, and who coordinates it? |
| Allergy or anesthesia concern | Allergy records, prior anesthesia notes | Which ingredient is the problem, and is there an alternative? |
| Unclear benefit for your diagnosis | Exact product name, cell source, route, trial or approval reference | What human data support this exact use, and what are alternatives? |
Ask for a written explanation of whether you need further assessment, should postpone, or should not receive the proposed intervention. Keep your records together through the stem cell treatment process in Japan, and distinguish provision-plan documentation from efficacy evidence when checking Japan’s registration and compliance rules.
Not sure whether a health condition rules you out?
Ask what records the treating medical team needs. Individual eligibility requires medical assessment.
Bottom line
Postpone an elective procedure while a significant medical risk remains unresolved. Avoid unsupported treatment offers rather than assuming that better health will make them effective. Keep established care in place, and make any transplant or clinical-trial decision with the relevant specialist.




